Skip to main content
SpringerLink
Log in
Book cover

Bone and Cancer pp 229–239Cite as

The Role of Allogeneic Bone Marrow Transplant in Cancer Treatment

  • Chapter
  • First Online:

  • 968 Accesses

Part of the book series: Topics in Bone Biology ((TBB,volume 5))

Abstract

Based on the observations [10,53] in animal models that the lethal myelosuppression induced by total body irradiation (TBI) could be overcome by the infusion of un-irradiated bone marrow, hematopoietic cell transplantation has evolved from idea to a well-established therapy used in the treatment of thousands of individuals around the world.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Anderlini P, Champlin RE. (2006) Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant. 12(6): 599–602.

    Article  PubMed  Google Scholar 

  2. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, et al. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 35(10):943–51.

    Article  PubMed  CAS  Google Scholar 

  3. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 8(3):145–54.

    Article  PubMed  CAS  Google Scholar 

  4. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, et al. (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 6(5A):548–54.

    Article  PubMed  CAS  Google Scholar 

  5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 11;335(2):91–7.

    Article  Google Scholar 

  6. Aversa F, Terenzi A, Felicini R, Carotti A, Falcinelli F, Tabilio A, et al. (2002) Haploidentical stem cell transplantation for acute leukemia. International Journal of Hematology. 76 Suppl 1:165–8.

    Article  PubMed  Google Scholar 

  7. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. (1968) Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. Lancet. 28;2(7583):1364–6.

    Article  Google Scholar 

  8. Balduzzi A. Valsecchi MG. Silvestri D. Locatelli F. Manfredini L. Busca A. Et al. et al. (2002) Transplant-related toxicity and mortality: an AEIOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant. 29(2):93–100

    Article  PubMed  CAS  Google Scholar 

  9. Barlogie B, Tricot GJ,van Rhee F, Angtuaco E, Walker R, EpsteinJ, et al. (2006). Long term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135; 158–164

    Article  PubMed  Google Scholar 

  10. Barnes DW, Corp MJ, Loutit JF, Neal FE. (1956) Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 2(4993):626–7.

    Article  PubMed  CAS  Google Scholar 

  11. Baron F, Storb R. (2007) Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol. 14(2):145–51.

    Article  PubMed  Google Scholar 

  12. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers MED et al. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 344(3):175–81

    Article  PubMed  CAS  Google Scholar 

  13. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 18:537–543

    PubMed  CAS  Google Scholar 

  14. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, et al. (1993). High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol. 4(9):767–73.

    PubMed  CAS  Google Scholar 

  15. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, et al. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 356:1110–20.

    Article  PubMed  CAS  Google Scholar 

  16. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet. 7;351(9104):700–8.

    Article  Google Scholar 

  17. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 118(2):385–400.

    Article  PubMed  Google Scholar 

  18. Butturini A, Bortin MM, Gale RP. (1987) Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 2(3):233–42.

    PubMed  CAS  Google Scholar 

  19. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 18:3918–3924.

    PubMed  CAS  Google Scholar 

  20. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 339(23): 1649–56.

    Article  PubMed  CAS  Google Scholar 

  21. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 99(6):1943–51.

    Article  PubMed  CAS  Google Scholar 

  22. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 348(19):1875–83.

    Article  PubMed  CAS  Google Scholar 

  23. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. (2007) Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 15;109(8):3588–94.

    Article  Google Scholar 

  24. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, et al. (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 106(9): 2969–76.

    Article  PubMed  CAS  Google Scholar 

  25. Dausset J, Rapaport FT, Colombani J, Feingold N. (1965) A leucocyte group and its relationship to tissue histocompatibility in man. Transplantation. (6): 701–5.

    Google Scholar 

  26. De Koning J, Van Bekkum DW, Dicke KA, Dooren LJ, Radl J, Van Rood JJ. (1969) Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet. 1(7608):1223–7.

    Article  PubMed  Google Scholar 

  27. de Lima M, Giralt S. (2006) Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol. 43(2):107–17.

    Article  PubMed  Google Scholar 

  28. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 100(4):1201–7.

    Article  PubMed  CAS  Google Scholar 

  29. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 21(1): 12–7.

    Article  PubMed  CAS  Google Scholar 

  30. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. (2007) Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 109(4):1395–400.

    Article  PubMed  CAS  Google Scholar 

  31. Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, et al. (2003) Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol. 120(2):281–8.

    Article  PubMed  Google Scholar 

  32. Fernandez MN, Regidor C, Cabrera R, Garcia-Marco JA, Fores R, Sanjuan I, et al. (2003) Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 31(6):535–44.

    Article  PubMed  Google Scholar 

  33. Ferrara J, Deeg H: Graft versus host disease. (1991) N Engl J Med 324:667–674.

    Article  PubMed  CAS  Google Scholar 

  34. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood.109(3):944–50.

    Article  PubMed  CAS  Google Scholar 

  35. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. (1995) Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 13(6):1312–22.

    PubMed  CAS  Google Scholar 

  36. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al et al. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease, J Clin Oncol. 14:572–578.

    PubMed  CAS  Google Scholar 

  37. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. (2006) Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107: 3474–3480.

    Article  PubMed  CAS  Google Scholar 

  38. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968 2(7583):1366–9.

    Article  Google Scholar 

  39. Gaziev D, Galimberti M, Lucarelli G, Polchi P. (2000) Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 25:689–696.

    Article  PubMed  CAS  Google Scholar 

  40. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89(12):4531–6.

    PubMed  CAS  Google Scholar 

  41. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, et al. (2007) Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 137(5):461–7.

    Article  PubMed  CAS  Google Scholar 

  42. Goldman JM. (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood. 110(8):2828–37.

    Article  PubMed  CAS  Google Scholar 

  43. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 90(8):2978–86.

    PubMed  CAS  Google Scholar 

  44. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 89(3):801–13.

    PubMed  CAS  Google Scholar 

  45. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, et al. (2004) Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 104(10):3028–37.

    Article  PubMed  CAS  Google Scholar 

  46. Jabbour E, Faderl S, Kantarjian H (2005): Adult acute lymphoblastic leukemia. Mayo Clin Proc. 80:1517–1527.

    Article  PubMed  CAS  Google Scholar 

  47. Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, et al. (1998) The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Br J Haematol. 102(5):1344–53.

    Article  PubMed  CAS  Google Scholar 

  48. Khouri I, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16(8):2817–24.

    PubMed  CAS  Google Scholar 

  49. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 98(13):3595–9.

    Article  PubMed  CAS  Google Scholar 

  50. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. (2003). Nonablative allogeneic stem cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol. 21:4407–4412.

    Article  PubMed  CAS  Google Scholar 

  51. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, et al. (1995). Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood. 85(6):1659–65

    PubMed  CAS  Google Scholar 

  52. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, et al. (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 14(2):246–55.

    Article  PubMed  Google Scholar 

  53. Lorenz E, Uphoff D, Reid TR, Shelton E. (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 12(1): 197–201

    PubMed  CAS  Google Scholar 

  54. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart M, Maziarz RT, et al. (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535–3542.

    Article  PubMed  CAS  Google Scholar 

  55. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 108(3): 836–46

    Article  PubMed  CAS  Google Scholar 

  56. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 25(9):1525–31.

    PubMed  CAS  Google Scholar 

  57. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. (2003) Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 101(5):2043–8.

    Article  PubMed  CAS  Google Scholar 

  58. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. (2007) Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 21(11):2324–31.

    Article  PubMed  CAS  Google Scholar 

  59. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, et al. (2004). Outcomes after alemtuzumab-containing reduced intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 104:3865–3871

    Article  PubMed  CAS  Google Scholar 

  60. Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, et al. (2007) Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant. 40(9):843–50.

    Article  PubMed  CAS  Google Scholar 

  61. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 101(4):1620–9.

    Article  PubMed  CAS  Google Scholar 

  62. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. (2007) Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 13(4):454–62.

    Article  PubMed  CAS  Google Scholar 

  63. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet. 365(9475):1934–1941

    Article  Google Scholar 

  64. Peggs KS, Mackinnon S, et al. (2005) The role of allogeneic transplantation in non-Hodgkin’s lymphoma. Br J Haematol. 128:153–168.

    Article  PubMed  Google Scholar 

  65. Perez-Simon JA, Martino R, Alegre A, Tomas JF, De Leon A, Caballero D, et al. (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol. 121(1):104–8.

    Article  PubMed  Google Scholar 

  66. Pui C, Evans W (2006): Treatment of acute lymphoblastic leukemia. N Engl J Med. 354:166–178.

    Article  PubMed  CAS  Google Scholar 

  67. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, et al. (2003). HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 102(1): 31–5.

    Article  PubMed  CAS  Google Scholar 

  68. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. (1996) Allogeneic vs. autologous stem cell transplantation vs. chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 10(12):1874–82.

    PubMed  CAS  Google Scholar 

  69. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernandez-Rivas JM, Moreno MJ, et al. (2005) Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 90(10):1346–56.

    PubMed  CAS  Google Scholar 

  70. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 100: 4310–4316

    Article  PubMed  CAS  Google Scholar 

  71. Rocha V, Gluckman E. (2006) Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant. 12(1 Suppl 1):34–41.

    Article  PubMed  Google Scholar 

  72. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 351(22):2276–85.

    Article  PubMed  CAS  Google Scholar 

  73. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 106(12):3760–7.

    Article  PubMed  CAS  Google Scholar 

  74. Rubinstein P, Carrier C, et al. (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 339(22):1565–77

    Article  PubMed  CAS  Google Scholar 

  75. Santos GW, Sensenbrenner LL, Anderson PN, Burke PJ, Klein DL, Slavin RE, et al. (1976) HL-A-identical marrow transplants in aplastic anemia, acute leukemia, and lymphosarcoma employing cyclophosphamide. Transplant Proc. 8(4):607–10.

    PubMed  CAS  Google Scholar 

  76. Schmitz N, Bacigalupo A, et al. (1998) Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21(10):995–1003.

    Article  PubMed  CAS  Google Scholar 

  77. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 359(9323):2065–71.

    Article  PubMed  CAS  Google Scholar 

  78. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 11(1):65–73.

    Article  PubMed  Google Scholar 

  79. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 100(6):1997–2004.

    PubMed  CAS  Google Scholar 

  80. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 16(1):31–42.

    PubMed  CAS  Google Scholar 

  81. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91(3): 756–63.

    PubMed  CAS  Google Scholar 

  82. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. (2008) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 111(1):446–52.

    Article  PubMed  CAS  Google Scholar 

  83. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, et al. (1999) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood. 94(3):1131–6.

    PubMed  CAS  Google Scholar 

  84. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. (2003)Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 102(4):1232–40.

    Article  PubMed  CAS  Google Scholar 

  85. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, et al . (2000) Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 14(6):1353–66.

    Article  PubMed  CAS  Google Scholar 

  86. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 49(4):511–33.

    PubMed  CAS  Google Scholar 

  87. Thomas ED, Buckner CD, Storb R. (1972) Aplastic anemia treated by marrow transplantation. Lancet. 1:284–9.

    Article  PubMed  CAS  Google Scholar 

  88. Thomas ED, Lochte HL, Jr., Lu WC, Ferrebee JW. (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 257(11):491–6.

    Article  PubMed  CAS  Google Scholar 

  89. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 22(20):4075–86.

    Article  PubMed  CAS  Google Scholar 

  90. Tomas J, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, Arranz R, Figuera A, Camara R, et al. (1996) Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplant. 17(6): 979–84

    CAS  Google Scholar 

  91. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B (1996) Graft-versus-myeloma effect: proof of principle. Blood. 87:1196–8

    PubMed  CAS  Google Scholar 

  92. Tutschka PJ, Copelan EA, Klein JP. (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 70(5):1382–8.

    PubMed  CAS  Google Scholar 

  93. Van Rood JJ, Eernisse JG, Van Leeuwen A. (1958) Leucocyte antibodies in sera from pregnant women. Nature. 181(4625):1735–6.

    Article  Google Scholar 

  94. Wagner JE, Barker JN, DeFor T, Baker KS, Blazar BR, Eide C, et al. (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood. 100:1611–1618.

    CAS  Google Scholar 

  95. Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ. (2007) Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 48(2):295–301.

    Article  PubMed  CAS  Google Scholar 

  96. Willemze R, Suciu S, Mandelli F, de Witte T, Amador S. (2004) Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 83 Suppl 1:S134.

    PubMed  Google Scholar 

  97. Wingard JR, Curbow B, Baker F, Piantadosi S. (1991) Health, functional status, and employment of adult survivors of bone marrow transplantation. Ann Intern Med. 114(2):113–8.

    PubMed  CAS  Google Scholar 

  98. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients – Report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 18(5): 963–71.

    PubMed  CAS  Google Scholar 

  99. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 332(4):217–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Centro Oncologico, MD Anderson International Espana, Madrid, Spain

    Jose Francisco Tomas MD, PhD

  2. University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

    Sergio A. Giralt (MD)

Authors
  1. Jose Francisco Tomas MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergio A. Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag London

About this chapter

Cite this chapter

Tomas, J.F., Giralt, S.A. (2010). The Role of Allogeneic Bone Marrow Transplant in Cancer Treatment. In: Bone and Cancer. Topics in Bone Biology, vol 5. Springer, London. https://doi.org/10.1007/978-1-84882-019-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-019-7_15

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-018-0

  • Online ISBN: 978-1-84882-019-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation